The Fund supports several networks of state health policymakers to help identify, inspire, and inform policy leaders.
The Fund identifies and shares policy ideas and analysis on topics important to state health policymakers, particularly on issues related to state leadership, primary care, aging, and total costs of care.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is an endowed operating foundation that publishes The Milbank Quarterly, commissions projects, and convenes state health policy decision makers on issues they identify as important to population health.
June 24, 2016
The Center for Evidence-based Policy
Back to News and Updates
As the end of the month approaches, so does the end of phase one of SMART-D, the State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs. A project of the Center for Evidence-based Policy (CEbP) at Oregon Health and Science University, SMART-D is part of a series of grants from the Laura and John Arnold Foundation in Houston, Texas, that address the rising cost of pharmaceutical drugs. The Center is a strategic partner of the Milbank Memorial Fund (MMF); the two organizations collaborate on promoting the development of evidence-informed health policymaking capacity in states.
SMART-D is aimed at developing a better menu of options for states to consider in purchasing high-cost drugs in Medicaid. Phase one of SMART-D concentrated on research, in which investigators looked at the current status of state Medicaid programs and high-cost drugs, including the options they have for paying for them. Researchers looked at four specific areas:
Before it is finalized, the work of phase one will be reviewed by an expert advisory panel convened by the MMF on behalf of the CEbP.
Phase two of the project will focus on planning—and help Medicaid programs identify potential collaborative agreements with drug manufacturers, focusing on patient outcomes and value-based reimbursements.
“States have a limited toolset in dealing with high-cost drugs,” says Pam Curtis, executive director of the CEbP. “Our work is focused on broadening the purchasing and cost management tools available to state Medicaid programs to ensure patient access to effective drugs that will improve health outcomes.” The goal of the project will be to pilot the alternative payment models between state Medicaid programs and drug manufacturers.
Jan 15, 2020
Dec 9, 2019
Get the Latest from the Milbank Memorial Fund
An endowed operating foundation that engages in nonpartisan analysis, collaboration, and communication, with an emphasis on state health policy.